4D Molecular Therapeutics, Inc. (FDMT)
$14.67-$0.24 (-1.61%) Today
Scott Bizily - OfficerScott Bizily - Officer4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
https://www.4dmoleculartherapeutics.comSEC filings for FDMT on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 13 | 302,980 | $3.69M |
| Grant or award | 7 | 375,000 | |
| Option exercise | 12 | 139,292 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
33 Form 4 filings on record, the earliest from Nov 13, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| John F. Milligan | Grant or award | Stock Option (Right to Buy) | 33,750 | $0.00 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Common Stock | 535,000 | $0.00 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Pre-Funded Warrants (Right to Buy) | 535,000 | - | - | |
| BVF PARTNERS L P | Other | Common Stock, $0.0001 par value | 3,062,000 | - | - | |
| BVF PARTNERS L P | Other | Common Stock, $0.0001 par value | 2,378,000 | - | - | |
| BVF PARTNERS L P | Other | Common Stock, $0.0001 par value | 240,000 | - | - | |
| BVF PARTNERS L P | Other | Pre-Funded Warrant | 3,062,000 | - | - | |
| BVF PARTNERS L P | Other | Pre-Funded Warrant | 2,378,000 | - | - | |
| BVF PARTNERS L P | Other | Pre-Funded Warrant | 240,000 | - | - |
This is as far as the anonymous view goes. Create a free account for all 33 FDMT filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| David Kirn | Officer | 69,076 | $1.16M | View on EDGAR | |
| SCOTT BIZILY | Officer | 6,540 | $80K | View on EDGAR | |
| SCOTT BIZILY | Officer | 1,635 | $19K | View on EDGAR |
4D Molecular Therapeutics, Inc. (FDMT) had 16 insider filings in the last 90 days, with the most recent on 2026-08-21. The full record for FDMT runs to 33 Form 4 filings, the earliest from 2024-11-13. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of FDMT were filed in the last 90 days.
13 insider sales of FDMT were filed in the last 90 days, totaling $3.69M.
This page tracks FDMT Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add FDMT to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
